The first Brazilian vaccine against bird flu will enter the clinical testing stage in humans, with the permission of the National Health Control Agency (AnVisa). Immunity is developed by the Puttan Institute in Sao Paulo.
The institute will recruit 700 volunteers Bernamboko countriesMinas Gerais and Sao Paulo. Participants will be divided into two age groups, between 18 and 59 years old and more than 60 years.
Those interested in participating in the test phase must provide for eligibility standards and be more than 18 years old. One model for registration of the participants has been provided NSTE link.
Pregnant women, women who are trying to get pregnant or breastfeeding, and people with controlled clinical condition, allergies of eggs and people or in the process of immunosuppressive treatment, cannot participate.
The initiative will evaluate the safety and immune effectiveness of the new vaccine. The test phase will lead researchers from Fiocruz Pernambuco and the Plastic Clinical Research Center, Rafael Dalia and Carlos Preto.
It displays the same test vaccine as a potential tool for creating effective antibodies against bird flu, and it works as a protective column to avoid new epidemic.
Rafael Dalia Research Center
Participants will receive two doses of vaccine or imaginary medicine. The separation between doses is 21 days. Only one of 7 volunteers will get the imaginary medicine.
The clinical study will be conducted at the seven -month -old clinical research center. At this time, the participants will accompany visits and examination to evaluate immune safety and immunity effectiveness.
A preliminary examination will also be performed with biochemical, bloody and serous chemical tests that will be done in the real Portuguese Hospital. The vaccine immunity analysis will be performed in Fiocruz pernambuco.
